Thoracic surface temperature rhythms as circadian biomarkers for cancer chronotherapy

Chronobiology International

Volumn 31, Issue 3, 2014, Pages 409-420

  Roche, Véronique Pasquale ^a,b,c   Mohamad Djafari, Ali ^d   Innominato, Pasquale Fabio ^a,c,e   Karaboué, Abdoulaye ^a   Gorbach, Alexander ^b   Lévi, Francis Albert ^a,c,e  

^a INSERM   (France)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d UNIV PARIS SUD   (France)

^e HÔPITAL PAUL BROUSSE   (France)

Author keywords

Chronotherapy; Circadian biomarkers; Colorectal cancer; Rest activity; Skin temperature

Indexed keywords

BIOLOGICAL MARKER;

AGED; ARTICLE; CHRONOTHERAPY; CIRCADIAN RHYTHM; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; NEOPLASM; PHYSIOLOGIC MONITORING; PHYSIOLOGY; SKIN TEMPERATURE; VERTEBRA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHRONOTHERAPY; CIRCADIAN RHYTHM; FEMALE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASMS; SKIN TEMPERATURE; THORACIC VERTEBRAE;

EID: 84897600958     PISSN: 07420528     EISSN: 15256073     Source Type: Journal    
DOI: 10.3109/07420528.2013.864301     Document Type: Article

References (53)

1. Ahowesso C, Li XM, Zampera S, et al. (2011). Sex and dosing-Time dependencies in irinotecan-induced circadian disruption. Chronobiol Int. 28:458-70
2. Bouchahda M, Adam R, Giacchetti S, et al. (2009). Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer. 115:4990-9
3. Bouchahda M, Macarulla T, Liedo G, et al. (2011). Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: A multicenter, retrospective analysis. Med Oncol. 28:S253-8
4. Bouchahda M, Macarulla T, Spano JP, et al. (2008). Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol. 67:255-62
5. Boudreau P, Shechter A, Dittmar A, et al. (2008). Cerebral temperature varies across circadian phases in humans. Conf Proc IEEE Eng Med Biol Soc. 2008:4856-8
6. Cavadini G, Petrzilka S, Kohler P, et al. (2007). TNF-Alpha suppresses the expression of clock genes by interfering with E-box-mediated transcription. Proc Natl Acad Sci USA. 104: 12843-8
7. Cohen L, Cole SW, Sood AK, et al. (2012). Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: Role of inflammatory signaling. PLoS One. 7: E42324
8. Del Bene VE. (1990). Temperature. In Walker HK, Hall WD, Hurst JW, eds. Clinical methods: The history, physical, and laboratory examinations. 3rd ed. Boston: Butterworths, Chapter 218
9. Filipski E, Innominato PF, Wu M, et al. (2005). Effects of light and food schedules on liver and tumor molecular clocks in mice. J Natl Cancer Inst. 97:507-17
10. Filipski E, King VM, Li X, et al. (2002). Host circadian clock as a control point in tumor progression. J Natl Cancer Inst. 94: 690-7
11. Filipski E, Lemaigre G, Liu XH, et al. (2004). Circadian rhythm of irinotecan tolerability in mice. Chronobiol Int. 21:613-30
12. Filipski E, Li XM, Lévi F. (2006). Disruption of circadian coordination and malignant growth. Cancer Causes Control. 17:509-14
13. Garaulet M, Madrid JA. (2009). Chronobiology, genetics and metabolic syndrome. Curr Opin Lipidol. 20:127-34
14. Garufi C, Dogliotti L, D'Attino RM, et al. (2001). Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: A phase I study. Cancer. 91:712-20
15. Gholam D, Giacchetti S, Brézault-Bonnet C, et al. (2006). Chronomodulated irinotecan, oxaliplatin, and leucovorinmodulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan-And oxaliplatin-resistant metastatic colorectal cancer. Oncologist. 11:1072-80
16. Giacchetti S, Bjarnason G, Garufi C, et al. (2006). Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol. 24:3562-9
17. Giacchetti S, Dugué PA, Innominato PF, et al. (2012). Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: A meta-Analysis. Ann Oncol. 23: 3110-16
18. Gunga HC, Werner A, Stahn A, et al. (2009). The double sensor-A non-invasive device to continuously monitor core temperature in humans on earth and in space. Respir Physiol Neurobiol. 169: S63-8
19. Innominato PF, Focan C, Gorlia T, et al. (2009). Circadian rhythm in rest and activity: A biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 69:4700-7
20. Innominato PF, Giacchetti S, Moreau T, et al.; for the ARTBC International Chronotherapy Group. (2011). Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-fluorouracil-leucovorin for metastatic colorectal cancer in a Randomized International Trial (EORTC 05963). Chronobiol Int. 28:586-600
21. Innominato PF, Giacchetti S, Bjarnason GA, et al. (2012). Prediction of overall survival through circadian rest-Activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer. 131:2684-92
22. Innominato PF, Giacchetti S, Moreau T, et al.; International Association for Research on Time in Biology and Chronotherapy (ARTBC Chronotherapy Group. (2013). Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. Cancer. 119:2564-73
23. Kornmann B, Schaad O, Reinke H, et al. (2007). Regulation of circadian gene expression in liver by systemic signals and hepatocyte oscillators. Cold Spring Harb Symp Quant Biol. 72: 319-30
24. Kramer A, Yang FC, Kraves S, Weitz CJ. (2005). A screen for secreted factors of the suprachiasmatic nucleus. Methods Enzymol. 393: 645-63
25. Kräuchi K (2002). How is the circadian rhythm of core body temperature regulated? Clin Auton Res. 12:147-9
26. Lévi F. (2001). Circadian chronotherapy for human cancers. Lancet Oncol. 2:30715 (Review)
27. Lévi F, Focan C, Karaboué A, et al. (2007). Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev. 59:1015-35
28. Lévi F, Karaboué A, Gorden L, et al. (2011). Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): Safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol. 67:339-48
29. Lévi F, Okyar A, Dulong S, et al. (2010). Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 50:377-421
30. Levi F, Parganiha A, Karaboué A, et al.; ARTBC International Chronotherapy Group. (submitted). Circadian robustness, an independent predictor of prolonged progression-free survival (PFS) and overall survival (OS) in 436 patients with metastatic colorectal cancer (mCRC). ASCO 2012 Gastrointestinal Cancers Symposium, 19-21 January 2012, San Francisco, USA
31. Li XM, Delaunay F, Dulong S, et al. (2010). Cancer inhibition through circadian reprogramming of tumor transcriptome with meal timing. Cancer Res. 70:3351-60
32. Li XM, Lévi F. (2007). Circadian physiology is a toxicity target of the anticancer drug gemcitabine in mice. J Biol Rhythms. 22:159-66
33. Li XM, Mohammad-Djafari A, Dumitru M, et al. (2013). A cricadian clock transcription model for the personalization of cancer chronotherapy. Cancer Res. 73(22). doi: 10.1158/0008-5472
34. Li XM, Vincenti M, Lévi F. (2002). Pharmacological effects of vinorelbine on body temperature and locomotor activity circadian rhythms in mice. Chronobiol Int. 19:43-55
35. Ma CL, Chang WP, Lin CC. (2013). Rest/activity rhythm is related to the coexistence of pain and sleep disturbance among advanced cancer patients with pain. Support Care Cancer. 22:87-94
36. Minors D, Waterhouse J, Folkard S, Atkinson G. (1996). The difference between activity when in bed and out of bed. III. Nurses on night work. Chronobiol Int. 13:273-82
37. Moore RY, Danchenko RL. (2002). Paraventricular-subparaventricular hypothalamic lesions selectively affect circadian function. Chronobiol Int. 19:345-60
38. Mormont MC, Waterhouse J, Bleuzen P, et al. (2000). Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 6:3038-45
39. Motohashi Y, Reinberg A, Levi F, et al. (1987). Axillary temperature: A circadian marker rhythm for shift workers. Ergonomics. 30: 1235-47
40. Ohdo S, Koyanagi S, Suyama H, et al. (2001). Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat Med. 7:356-60
41. Ortiz-Tudela E, Martinez-Nicolas A, Campos M, et al. (2010). A new integrated variable based on thermometry, actimetry and body position (TAP) to evaluate circadian system status in humans. PLoS Comput Biol. 6:e1000996
42. Ortiz-Tudela E, Mteyrek A, Ballesta A, et al. (2013). Cancer chronotherapeutics: Experimental, theoretical, and clinical aspects. Handb Exp Pharmacol. 217:261-88
43. Portaluppi F, Smolensky MH, Touitou Y. (2010). Ethics and methods for biological rhythm research on animals and human beings. Chronobiol Int. 27:1911-29
44. Reinke H, Saini C, Fleury-Olela F, et al. (2008). Differential display of DNA-binding proteins reveals heat-shock factor 1 as a circadian transcription factor. Genes Dev. 22:331-45
45. Rich T, Innominato PF, Boerner J, et al. (2005). Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-Activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res. 11:1757-64
46. Schey BM, Williams DY, Bucknall T. (2009). Skin temperature as a noninvasive marker of haemodynamic and perfusion status in adult cardiac surgical patients: An observational study. Intensive Crit Care Nurs. 25:31-7
47. Scully CG, Karaboué A, Liu WM, et al. (2011). Skin surface temperature rhythms as potential circadian biomarkers for personalized chronotherapeutics in cancer patients. Interface Focus. 1:48-60
48. Sephton SE, Lush E, Dedert EA, et al. (2013). Diurnal cortisol rhythm as a predictor of lung cancer survival. Brain Behav Immun. 30:S163-70
49. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. (2000). Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 92:994-1000
50. Silver R, LeSauter J. (1993). Efferent signals of the suprachiasmatic nucleus. J Biol Rhythms. 8:S89-92
51. Silver R, Schwartz WJ. (2005). The suprachiasmatic nucleus is a functionally heterogeneous timekeeping organ. Methods Enzymol. 393:451-65
52. Waterhouse J, Fukuda Y, Morita T. (2012). Daily rhythms of the sleep-wake cycle. J Physiol Anthropol. 31:5 (1-9) (Review
53. Wu MW, Li XM, Xian LJ, Lévi F. (2004). Effects of meal timing on tumor progression in mice. Life Sci. 75:1181-93